BioLineRx (NASDAQ: BLRX) reported Q1 EPS of $0.00, $0.10 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $3.96 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.